{
  "ticker": "PTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969447",
  "id": "02969447",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250715",
  "time": "1301",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250715/pdf/06ltbl3trtvxq2.pdf",
  "summary": "### **Capital Raising Announcement Summary (Securities Purchase Plan - SPP)**  \n- **Structure**: Offer under a **Securities Purchase Plan (SPP)**  \n- **Maximum Capital to be Raised**: AUD **$7 million** (with discretion to increase/scale back)  \n- **Offer Price**: AUD **$0.04 per share**  \n- **Key Dates**:  \n  - **Record Date**: 30 June 2025  \n  - **Closing Date**: **Extended to 22 July 2025** (from 15 July 2025)  \n  - **Issue Date**: 30 July 2025  \n- **Offer Terms**:  \n  - Eligible shareholders can apply for parcels of AUD **$5,000\u2013$30,000**.  \n  - Scale-back may apply if oversubscribed; PTX may adjust offer size.  \n- **Use of Proceeds**: Fund Phase 2 clinical trials for **PTX-100** (cancer therapy), working capital, and offer costs.  \n- **Broker Fee**: 6% of funds raised + call options (1:20 ratio, strike $0.06, 4-year expiry).  \n- **Ineligible Shareholders**: Outside Australia/NZ.  \n\n**Material Change**: Extension of closing date (**22 July 2025**).",
  "usage": {
    "prompt_tokens": 2213,
    "completion_tokens": 275,
    "total_tokens": 2488,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-15T03:24:28.500969"
}